|
1
|
Ryan D, Hong T and Bardeesy N: Pancreatic
adenocarcinoma. N Engl J Med. 371:2140–2141. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Uesaka K, Boku N, Fukutomi A, Okamura Y,
Konishi M, Matsumoto I, Kaneoka Y, Shimizu Y, Nakamori S, Sakamoto
H, et al: Adjuvant chemotherapy of S-1 versus gemcitabine for
resected pancreatic cancer: A phase 3, open-label, randomised,
non-inferiority trial (JASPAC 01). Lancet. 388:248–257. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Picozzi VJ, Oh SY, Edwards A, Mandelson
MT, Dorer R, Rocha FG, Alseidi A, Biehl T, Traverso LW, Helton WS,
et al: Five-year actual overall survival in resected pancreatic
cancer: A contemporary single-institution experience from a
multidisciplinary perspective. Ann Surg Oncol. 24:1722–1730. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Rulyak S, Lowenfels A, Maisonneuve P and
Brentnall T: Risk factors for the development of pancreatic cancer
in familial pancreatic cancer kindreds. Gastroenterology.
124:1292–1299. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Huxley R, Ansary-Moghaddam A, Berrington
De González A, Barzi F and Woodward M: Type-II diabetes and
pancreatic cancer: A meta-analysis of 36 studies. Br J Cancer.
92:2076–2083. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Liu QC, Zhuang ZH, Zeng K, Cheng ZJ, Gao F
and Wang ZQ: Prevalence of pancreatic diabetes in patients carrying
mutations or polymorphisms of the PRSS1 gene in the Han population.
Diabetes Technol Ther. 11:799–804. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Winter JM, Yeo CJ and Brody JR:
Diagnostic, prognostic, and predictive biomarkers in pancreatic
cancer. J Surg Oncol. 107:15–22. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Hausmann S, Kong B, Michalski C, Erkan M
and Friess H: The role of inflammation in pancreatic cancer. Adv
Exp Med Biol. 816:129–151. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Pinho A, Chantrill L and Rooman I: Chronic
pancreatitis: A path to pancreatic cancer. Cancer Lett.
345:203–209. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Weiss F: Pancreatic cancer risk in
hereditary pancreatitis. Front Physiol. 5:702014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Whitcomb DC: Genetic risk factors for
pancreatic disorders. Gastroenterology. 144:1292–1302. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Gao F, Li YM, Hong GL, Xu ZF, Liu QC, He
QL, Lin LQ and Weng SH: PRSS1_p.Leu81Met mutation results in
autoimmune pancreatitis. World J Gastroenterol. 19:3332–3338. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Gao F, Liu QC, Zhang S, Zhuang ZH, Lin CZ
and Lin XH: PRSS1 intron mutations in patients with pancreatic
cancer and chronic pancreatitis. Mol Med Rep. 5:449–451.
2012.PubMed/NCBI
|
|
14
|
Hengstler JG, Bauer A, Wolf HK, Bulitta
CJ, Tanner B, Oesch F, Gebhard S and Boettger T: Mutation analysis
of the cationic trypsinogen gene in patients with pancreatic
cancer. Anticancer Res. 20:2967–2974. 2000.PubMed/NCBI
|
|
15
|
Rebours V, Boutron-Ruault M, Schnee M,
Férec C, Maire F, Hammel P, Ruszniewski P and Lévy P: Risk of
pancreatic adenocarcinoma in patients with hereditary pancreatitis:
A national exhaustive series. Am J Gastroenterol. 103:111–119.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Chen J and Férec C: Chronic pancreatitis:
Genetics and pathogenesis. Annu Rev Genomics Hum Genet. 10:63–87.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Liu Q, Lin X, Liu J, Liu A and Gao F: The
−409 C/T genotype of PRSS1 protects against pancreatic cancer in
the Han Chinese population. Dig Dis Sci. 57:573–579. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zeng K, Liu QC, Lin JH, Lin XH, Zhuang ZH,
Gao F and Ou QS: Novel mutations of PRSS1 gene in patients with
pancreatic cancer among Han population. Chin Med J (Engl).
124:2065–2067. 2011.PubMed/NCBI
|
|
19
|
Yi Q, Dong F, Lin L, Liu Q, Chen S, Gao F
and He Q: PRSS1 mutations and the proteinase/antiproteinase
imbalance in the pathogenesis of pancreatic cancer. Tumour Biol.
37:5805–5810. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Campa D, Pastore M, Capurso G, Hackert T,
Di Leo M, Izbicki JR, Khaw KT, Gioffreda D, Kupcinskas J, Pasquali
C, et al: Do pancreatic cancer and chronic pancreatitis share the
same genetic risk factors? A PANcreatic Disease ReseArch (PANDoRA)
consortium investigation. Int J Cancer. 142:290–296. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Gargiulo S, Torrini M, Ollila S, Nasti S,
Pastorino L, Cusano R, Bonelli L, Battistuzzi L, Mastracci L, Bruno
W, et al: Germline MLH1 and MSH2 mutations in Italian pancreatic
cancer patients with suspected Lynch syndrome. Fam Cancer.
8:547–553. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Fogelman D, Wolff R, Kopetz S, Javle M,
Bradley C, Mok I, Cabanillas F and Abbruzzese J: Evidence for the
efficacy of Iniparib, a PARP-1 inhibitor, in BRCA2-associated
pancreatic cancer. Anticancer Res. 31:1417–1420. 2011.PubMed/NCBI
|
|
23
|
Berger AC, Garcia M Jr, Hoffman JP, Regine
WF, Abrams RA, Safran H, Konski A, Benson AB III, MacDonald J and
Willett CG: Postresection CA 19-9 predicts overall survival in
patients with pancreatic cancer treated with adjuvant
chemoradiation: A prospective validation by RTOG 9704. J Clin
Oncol. 26:5918–5922. 2008. View Article : Google Scholar : PubMed/NCBI
|
